Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Scarpi

Showing results (171-180 of 216) with videos related to

Pageof 22
Sort By:
BMC Cancer|March 29, 2018
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|March 12, 2020
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a <i>post hoc</i> analysis of the IBIS 3 trialSara Bravaccini, Giuseppe Bronte, Emanuela Scarpi, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
International Journal of Molecular Sciences|September 23, 2022
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and PancreasJessica Iorio, Lorenzo Antonuzzo, Emanuela Scarpi, et al.
Annals of Surgical Oncology|May 28, 2013
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)Giovenzio Genestreti, Luca Ampollini, Marco Angelo Burgio, et al.
Urologic Oncology|February 7, 2018
Association among metabolic syndrome, inflammation, and survival in prostate cancerVincenza Conteduca, Orazio Caffo, Luca Galli, et al.
Pageof 22

Showing results (171-180 of 216) with videos related to

Sort By:
Pageof 22
BMC Cancer|March 29, 2018
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|March 12, 2020
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a <i>post hoc</i> analysis of the IBIS 3 trialSara Bravaccini, Giuseppe Bronte, Emanuela Scarpi, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
International Journal of Molecular Sciences|September 23, 2022
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and PancreasJessica Iorio, Lorenzo Antonuzzo, Emanuela Scarpi, et al.
Annals of Surgical Oncology|May 28, 2013
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)Giovenzio Genestreti, Luca Ampollini, Marco Angelo Burgio, et al.
Urologic Oncology|February 7, 2018
Association among metabolic syndrome, inflammation, and survival in prostate cancerVincenza Conteduca, Orazio Caffo, Luca Galli, et al.
Pageof 22